Date: 2017-04-26
Type of information: Production agreement
Compound: TIL (tumor infiltrating lymphocyte) products
Company: Lion Biotechnologies (USA - CA) Pharmacell (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing - production
Action mechanism:
- cell therapy/immunotherapy product. Tumor infiltrating lymphocytes (TIL) have the capacity to recognize and attack the tumor traffic and infiltrate into the tumor. However, the anti-tumor effect of these cells is usually short-lived because cancer cells adapt and suppress the anti-tumor immune response through the release of various anti-inflammatory factors into the local environment. Here, TIL are first extracted from the patient and expanded in tissue culture with IL-2. Then the amplification process eliminates the immune-suppressive environment created by the tumor which is so effective at neutralizing the natural anti-tumor immune response. Third, this same culture environment optimizes the replication and activation of aggressive anti-tumor TIL. Once sufficient numbers of cells with the appropriate anti-tumor potential have been cultured, they are then re-administered back into the donor patient where they have been shown to mediate impressive anti-tumor responses.
Disease:
Details:
- • On April 26, 2017, Lion Biotechnologies announced that it has entered into a new three-year manufacturing services agreement and related statements of work with PharmaCell, a contract manufacturing services company based in the Netherlands, to manufacture its autologous cell therapy products. PharmaCell will manufacture TIL products for Lion in its clinical and commercial facility in Geleen, the Netherlands. This collaboration will increase Lion's TIL manufacturing as the company is expanding its clinical trial program in Europe.
Financial terms:
Latest news:
Is general: Yes
